Literature DB >> 6339177

In vitro protection of group A beta-hemolytic streptococci from penicillin and cephalothin by Bacteroides fragilis.

I Brook, P Yokum.   

Abstract

beta-Lactamase produced by Bacteroides fragilis could protect from antibiotics group A beta-hemolytic streptococci (GABHS), penicillin-susceptible pathogens frequently isolated from acute tonsillitis in children. To test this hypothesis we determined the minimal bactericidal concentration (MBC) to penicillin and cephalothin of GABHS alone and in mixed culture with eleven beta-lactamase-producing strains of B. fragilis. B. fragilis strains with MBC values less than or equal to 32 micrograms/ml to penicillin and less than or equal to 64 micrograms/ml to cephalothin did not provide any protection for GABHS. However, strains with MBC greater than or equal to 128 micrograms/ml to penicillin and greater than or equal to 256 micrograms/ml to cephalothin provided protection by increasing the MBC of GABHS at least 8,534 times for penicillin and 2,048 times for cephalothin. This phenomenon was most marked in 5% CO2. B. fragilis provided no protection against clindamycin. These results may explain the inability of penicillin therapy to completely eradicate GABHS from cases of recurrently infected tonsils.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339177     DOI: 10.1159/000238168

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  Emergence of beta-lactamase producing anaerobic bacteria in the tonsils during penicillin treatment.

Authors:  K Tunér; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

2.  Impact on peritonsillar infections and microflora of phenoxymethylpenicillin alone versus phenoxymethylpenicillin in combination with metronidazole.

Authors:  K Tunér; C E Nord
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

3.  Tonsil surface and core cultures in recurrent tonsillitis: prevalence of anaerobes and beta-lactamase producing organisms.

Authors:  I J Mitchelmore; P G Reilly; A J Hay; S Tabaqchali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

4.  Rapid method for detecting beta-lactamase producing bacteria in clinical specimens.

Authors:  I Brook; A E Gober
Journal:  J Clin Pathol       Date:  1984-12       Impact factor: 3.411

5.  β-Lactamase-Producing Bacteria in Upper Respiratory Tract Infections.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

6.  Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with group A beta-hemolytic streptococci.

Authors:  I Brook; J D Gilmore
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Direct and indirect pathogenicity of Branhamella catarrhalis.

Authors:  I Brook
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule.

Authors:  I Brook; A E Gober; F Leyva
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 9.  The role of beta-lactamase-producing-bacteria in mixed infections.

Authors:  Itzhak Brook
Journal:  BMC Infect Dis       Date:  2009-12-14       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.